Chicago—Researchers have known for some time that the use of iodinated agents in contrast studies is associated with a risk of contrast-induced nephropathy (CIN) and that the risk is greater for those with compromised renal function. More recently, evidence has emerged that use of gadolinium-based agents is associated with a risk of another condition, nephrogenic systemic fibrosis (NSF), which has been reported only in persons with kidney disease.
Research presented at the Radiological Society of North America's annual meeting here in November reflects scientists' efforts to better understand these adverse effects and how to reduce the likelihood such problems will occur.
Chang HJ. Researchers Focus on Contrast Safety. JAMA. 2010;303(13):1244. doi:10.1001/jama.303.13.1244